SCHEMBL6478164

SCHEMBL6478164

CCCCC(CC)CN(N)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.47
KDM4E B2RXH2 2/20 0.47
TDP1 Q9NUW8 1/20 0.41
CYP3A4 P08684 3/20 0.41
CA2 P00918 1/20 0.41
TSHR P16473 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.38
MAPT P10636 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
LMNA P02545 3/20 0.38
HSD17B10 Q99714 2/20 0.37
PRSS1 P07477 1/20 0.36
PRSS2 P07478 1/20 0.36
PRSS3 P35030 1/20 0.36
MAPK1 P28482 2/20 0.36
HDAC3 O15379 2/20 0.34
HDAC4 P56524 2/20 0.34
HDAC1 Q13547 2/20 0.34
HDAC7 Q8WUI4 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6477129 0.86 AOC3 (0.38) ALDH1A1KDM4ETDP1CYP3A4TSHR
SCHEMBL411231 0.83 ALDH1A1 (0.49) ALDH1A1KDM4ETDP1CYP3A4CA2
SCHEMBL411184 0.83 ALDH1A1 (0.49) ALDH1A1KDM4ETDP1CYP3A4CA2
Hydrochloric Acid SCHEMBL11413011 0.81 ALDH1A1 (0.48) ALDH1A1KDM4ETDP1CYP3A4CA2
SCHEMBL11722797 0.81 ALDH1A1 (0.48) ALDH1A1KDM4ETDP1CYP3A4CA2
SCHEMBL28776481 0.80 ALDH1A1 (0.50) ALDH1A1KDM4ETDP1CYP3A4CA2
SCHEMBL8438717 0.80 ALDH1A1 (0.47) ALDH1A1KDM4ETDP1CYP3A4CA2
SCHEMBL8438809 0.79 ALDH1A1 (0.46) ALDH1A1KDM4ETDP1CYP3A4CA2
SCHEMBL8440732 0.79 ALDH1A1 (0.46) ALDH1A1KDM4ETDP1CYP3A4CA2
SCHEMBL28385206 0.78 ALDH1A1 (0.44) ALDH1A1KDM4ETDP1CYP3A4CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887863-B2 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES (US) 2005-05-03 US disclosed
EP-1272456-B1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LAB (US) 2004-10-27 EP disclosed
US-20040167126-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBVIE INC. 2004-08-26 US disclosed
EP-1272456-A1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS Abbott Laboratories (US) 2003-01-08 EP disclosed
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES 2002-01-03 US disclosed
WO-2001079157-A1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167126-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP ALDH1A1 583/4885KDM4E 1796/4885TDP1 3859/4885
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP ALDH1A1 583/4885KDM4E 1796/4885TDP1 3859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.